Dr Joaquin Mateo speaks to ecancer in an online interview about the current landscape of PARP inhibitors for the treatment of prostate cancer.
He gives an overview of the PROfound trial which is looking at olaparib for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2 or ATM mutations.
Dr Mateo also describes other studies he has been involved with, including a study identifying how often these DNA repair defects are inherited and presented in the germline DNA - which could be relevant for the patient's family too.
For the future, he believes that the incorporation of genomics to stratify patients in this way is extremely promising and rapidly-progressing.
Dr Mateo also acknowledges the risk of resistance to this type of targeted therapy, but remains optimistic about the benefits as future trials will explore the other drug combinations with PARP inhibitors.
This programme has been supported by an unrestricted educational grant from Pfizer.